Hussman Strategic Advisors Inc. Acquires Shares of 210,000 Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Hussman Strategic Advisors Inc. purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 210,000 shares of the biotechnology company's stock, valued at approximately $1,688,000. Hussman Strategic Advisors Inc. owned 0.15% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in Aurinia Pharmaceuticals during the 4th quarter worth approximately $27,000. Tower Research Capital LLC TRC lifted its stake in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after buying an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $31,000. GAMMA Investing LLC lifted its stake in Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after buying an additional 1,744 shares in the last quarter. Finally, Natixis bought a new position in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $49,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Stock Down 4.9%

AUPH traded down $0.44 during trading on Friday, reaching $8.63. 2,005,192 shares of the stock were exchanged, compared to its average volume of 1,408,574. The stock has a market cap of $1.17 billion, a P/E ratio of 30.82 and a beta of 1.16. Aurinia Pharmaceuticals Inc has a twelve month low of $5.20 and a twelve month high of $10.67. The stock's 50 day moving average price is $8.15 and its two-hundred day moving average price is $8.07. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.26 and a current ratio of 5.93.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. The business had revenue of $62.47 million for the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a net margin of 16.11% and a return on equity of 14.27%. Equities analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.